// App-Quantinova.ai

POS0919 (2021) : BIMEKIZUMAB SHOWS SUSTAINED LONG-TERM IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES AND QUALITY OF LIFE IN ANKYLOSING SPONDYLITIS: 3-YEAR RESULTS FROM A PHASE 2B STUDY

Researchers

Presenter

  • X. Baraliakos

Principal Investigators

  • M. Dougados

  • K. Gaffney

  • R. Sengupta

  • M. Magrey

  • N. De Peyrecave

  • M. Oortgiesen

  • T. Vaux

  • C. Fleurinck

  • A. Deodhar

Medical Centers

  • Ruhr-University Bochum, Rheumazentrum Ruhrgebiet, Bochum, Germany

  • APHP Hopital Cochin Department of Dermatology, Paris, France

  • Norfolk and Norwich University Hospitals NHS Trust, Rheumatology Department, Norwich, United Kingdom

  • Royal National Hospital for Rheumatic Diseases NHS Trust, Department of Rheumatology, Bath, United Kingdom

  • Case Western Reserve University, MetroHealth Medical Center, Cleveland, United States of America

  • UCB Pharma, Brussels, Belgium

  • UCB Pharma, Raleigh, United States of America

  • UCB Pharma, Slough, UK Slough United Kingdom

  • Oregon Health and Science University, Rheumatology Clinica Division of Arthritis and Rheumatic Diseases, Portland, United States of America

Locations

  • Germany

  • France

  • United Kingdom

  • United States

  • Belgium

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Musculoskeletal

Disease

  • Ankylosing spondylitis

Biomarkers

  • Nutritional risk screening

Drug/Treatment

  • bimekizumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT02963506

  • NCT03355573

Sponsors

  • UCB

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved